McKesson Signs Agreement to Acquire Precision Medicine Group, LLC
Business Wire (Tue, 25-Aug 8:00 AM ET)
McKesson Reports Fiscal 2027 First Quarter Results and Raises Full Year Adjusted EPS Guidance
Business Wire (Wed, 5-Aug 4:10 PM ET)
McKesson Corporation Raises Quarterly Dividend by 15% to $0.94 Per Share
Business Wire (Wed, 22-Jul 8:00 AM ET)
McKesson Corporation Announces First Quarter Fiscal 2027 Earnings Release Date
Business Wire (Wed, 24-Jun 8:00 AM ET)
McKesson Plots CFO Transition Amid Record Results and Strategic Realignment
Market Chameleon (Thu, 5-Mar 4:09 AM ET)
McKesson Lifts Full-Year EPS Outlook—What Does This Mean for Investors?
Market Chameleon (Thu, 5-Feb 6:10 AM ET)
McKesson is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Mckesson trades on the NYSE stock market under the symbol MCK.
As of September 14, 2026, MCK stock price climbed to $910.70 with 423,436 million shares trading.
MCK has a beta of -0.15, meaning it tends to be less sensitive to market movements. MCK has a correlation of 0.00 to the broad based SPY ETF.
MCK has a market cap of $106.18 billion. This is considered a Large Cap stock.
Last quarter Mckesson reported $105 billion in Revenue and $9.93 earnings per share. This beat revenue expectation by $1 billion and exceeded earnings estimates by $.31.
In the last 3 years, MCK traded as high as $999.00 and as low as $417.65.
The top ETF exchange traded funds that MCK belongs to (by Net Assets): VTI, VOO, IVV, SPY, VTV.
MCK has outperformed the market in the last year with a price return of +27.0% while the SPY ETF gained +16.9%. MCK has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +15.8% and +2.0%, respectively, while the SPY returned +3.5% and -1.0%, respectively.
MCK support price is $866.78 and resistance is $896.24 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MCK shares will trade within this expected range on the day.
